Teva Pharmaceutical Industries Ltd. is recalling 792,603 asthma inhalers because they failed tests to ensure they had identical contents.
The recall began Nov. 23 and affects prescription ProAir HFA inhalers sold nationwide, the U.S. Food and Drug Administration said in a notice available on its website today.
Respiratory products accounted for $898 million, or 6.5 percent, of Teva’s revenue in 2009. The Petah Tikva, Israel-based company, the world’s largest maker of generic drugs, said the irregularities with the four batches of ProAir HFA have no impact on patients. Three of the lots have expired and one expires this month.
“We continue to work through our investigation and are keeping FDA informed of our findings,” Denise Bradley, a U.S. spokeswoman for Teva, said today in an e-mail.